

CSD/BSE&NSE/PR/2026-2027

July 10, 2026

**To**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai – 400001**

**To**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: News Release**

-----

With reference to above subject, please find enclosed News Release of our company titled **“Suven Life Sciences to Present Five Scientific Posters, Including Global Phase-3 Masupirdine Study Updates and Usmarapride Phase-2 clinical development program at Alzheimer's Association International Conference (A Global Forum to Advance Dementia Science) AAIC-2026 during 12-15 July, 2026 in London, UK.”**

This is for your information and record.

Thanking you.  
Yours faithfully,  
For **Suven Life Sciences Limited**

**K. Sangeetha Laxmi**  
Company Secretary

Encl.: as above

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

## News Release

### **Suven Life Sciences to Present Five Scientific Posters, Including Global Phase-3 Masupirdine Study Updates and Usmapridine Phase-2 clinical development program at Alzheimer's Association International Conference (A Global Forum to Advance Dementia Science) AAIC-2026 during 12-15 July, 2026 in London, UK.**

Hyderabad, India, 10-July-2026 - Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced its participation at the Alzheimer's Association International Conference (AAIC) 2026, A Global Forum to Advance Dementia Science, to be held during 12–15, July 2026, in London, United Kingdom. During the conference, the Company will present five scientific posters, including an update on its ongoing global Phase-3 Masupirdine clinical program for Agitation associated with Alzheimer's Dementia and Usmapridine Phase-2 clinical development program.

The AAIC is the largest international conference dedicated to advancing dementia science and clinical practice. Each year, AAIC convenes researchers, clinicians and dementia professionals from all career stages to share breaking research discoveries and clinical practice education that will lead to improvements in diagnosis, risk reduction and treatments for Alzheimer's disease and other dementias.

At AAIC 2026, Suven Life Sciences will present updates from its ongoing global Phase-3 Masupirdine study, including demographic and clinical characteristics of enrolled patients, providing insights into the study population and trial progress in agitation associated with Alzheimer's disease dementia. The company will also showcase broader non-clinical and clinical research advances across its neuroscience pipeline, engage with investigators, key opinion leaders, and the global research community, and explore strategic partnering opportunities for its clinical-stage CNS portfolio with pharmaceutical and biotechnology companies.

#### **Suven Presentations:**

- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a M1 PAM, in Healthy Human Subjects (**Sunday-0178, 12<sup>th</sup> July, 7:30 AM - 4.15 PM**).
- SUVN-L1101142: A Muscarinic 4 Positive Allosteric Modulator for the Treatment of Alzheimer's Disease and Schizophrenia (**Monday-0321, 13<sup>th</sup> July, 7:30 AM - 4:15 PM**).
- Masupirdine (A Pure 5-HT<sub>6</sub>R Antagonist): Updates from the Phase-3 Clinical Trial Program Targeting Agitation in Alzheimer's Dementia (**Wednesday-0043, 15<sup>th</sup> July, 7:30 AM - 4:15 PM**).

### **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)

- Usmarapride, selective 5-HT<sub>4</sub>R partial agonist: an update on the clinical development program for the treatment of cognitive disorders (**Wednesday-0436, 15<sup>th</sup> July, 7:30 AM - 4:15 PM**).
- Efficacy and Safety of SUVN-N9503012, a Selective 5-HT<sub>1A</sub> Partial Agonist for the Symptomatic Treatment of Neurodegenerative Disorders (**Wednesday-0943, 15<sup>th</sup> July, 7:30 AM - 4:15 PM**).

Conference attendees are invited to visit Suven's Exhibit Booth #117, where members of the Company's scientific and business development teams will be available throughout the meeting to discuss its clinical-stage neuroscience pipeline, ongoing development programs, future development strategy, and potential collaboration and partnering opportunities.

**About Suven Life Sciences:** Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for treatment of narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b proof of concept study completed); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study completed). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website <http://www.suven.com>

**Risk Statement:** *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)